Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
NCT03252353 is registered in ClinicalTrials.gov with Chiasma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment
- Lead sponsor
- Chiasma, Inc.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- September 1, 2017
- Completion date
- May 31, 2022
- Enrollment
- 56 (actual)
- Sites
- 60
Conditions
As the registry lists them; a condition with its own page is linked.